162 related articles for article (PubMed ID: 24359969)
21. Evaluation of an automated method for measuring von Willebrand factor activity in clinical samples without ristocetin.
Graf L; Moffat KA; Carlino SA; Chan AK; Iorio A; Giulivi A; Hayward CP
Int J Lab Hematol; 2014 Jun; 36(3):341-51. PubMed ID: 24750681
[TBL] [Abstract][Full Text] [Related]
22. Platelet activation and aggregation induced by recombinant von Willebrand factors reproducing four type 2B von Willebrand disease missense mutations.
de Romeuf C; Hilbert L; Mazurier C
Thromb Haemost; 1998 Jan; 79(1):211-6. PubMed ID: 9459349
[TBL] [Abstract][Full Text] [Related]
23. Enzymes that hydrolyze adenine nucleotides in platelets and polymorphisms in the alpha2 gene of integrin alpha2beta1 in patients with von Willebrand disease.
Santos KF; Battisti V; Corrêa Mde C; Mann TR; Pereira Rda S; Araújo Mdo C; Brülê AO; Schetinger MR; Morsch VM
Mol Cell Biochem; 2010 Jul; 340(1-2):249-56. PubMed ID: 20336352
[TBL] [Abstract][Full Text] [Related]
24. New insights into von Willebrand disease and platelet function.
Szántó T; Joutsi-Korhonen L; Deckmyn H; Lassila R
Semin Thromb Hemost; 2012 Feb; 38(1):55-63. PubMed ID: 22314604
[TBL] [Abstract][Full Text] [Related]
25. Platelets compensate for poor thrombin generation in type 3 von Willebrand disease.
Szanto T; Nummi V; Jouppila A; Brinkman HJM; Lassila R
Platelets; 2020; 31(1):103-111. PubMed ID: 30836803
[TBL] [Abstract][Full Text] [Related]
26. Red cell-derived microparticles (RMP) as haemostatic agent.
Jy W; Johansen ME; Bidot C; Horstman LL; Ahn YS
Thromb Haemost; 2013 Oct; 110(4):751-60. PubMed ID: 24030707
[TBL] [Abstract][Full Text] [Related]
27. Von Willebrand's disease.
Hoyer LW
Prog Hemost Thromb; 1976; 3():231-87. PubMed ID: 781732
[No Abstract] [Full Text] [Related]
28. [Use of frozen thrombocytes for the determination of von willebrand factor with the aid of ristocetin].
Caduff T; Straub PW
Schweiz Med Wochenschr; 1979 Mar; 109(11):399-402. PubMed ID: 34214
[TBL] [Abstract][Full Text] [Related]
29. A rapid, automated VWF ristocetin cofactor activity assay improves reliability in the diagnosis of Von Willebrand disease.
Bowyer AE; Shepherd F; Kitchen S; Makris M
Thromb Res; 2011 Apr; 127(4):341-4. PubMed ID: 21186048
[TBL] [Abstract][Full Text] [Related]
30. Platelet-bound ristocetin aggregation factor in normal subjects and patients with von Willebrand's disease.
Green D; Potter EV
J Lab Clin Med; 1976 Jun; 87(6):976-86. PubMed ID: 778313
[TBL] [Abstract][Full Text] [Related]
31. Effect of the Novel Biodegradable N, O-Carboxymethylchitosan and Oligo-Chitosan on the Platelet Thrombogenicity Cascade in von Willebrand Disease.
Periayah MH; Halim AS; Mat Saad AZ; Yaacob NS; Hussein AR; Abdul Karim F; Abdul Rashid AH; Ujang Z
Thromb Res; 2015 Sep; 136(3):625-33. PubMed ID: 26254703
[TBL] [Abstract][Full Text] [Related]
32. Further studies on aggregation of platelet-type von Willebrand's disease platelets by human von Willebrand factor.
Takahashi H; Tatewaki W; Hanano M; Nagayama R; Shibata A
Thromb Haemost; 1986 Jun; 55(3):338-41. PubMed ID: 3018956
[TBL] [Abstract][Full Text] [Related]
33. Laboratory diagnosis and molecular classification of von Willebrand disease.
Gadisseur A; Hermans C; Berneman Z; Schroyens W; Deckmyn H; Michiels JJ
Acta Haematol; 2009; 121(2-3):71-84. PubMed ID: 19506352
[TBL] [Abstract][Full Text] [Related]
34. Increased neonatal platelet deposition on subendothelium under flow conditions: the role of plasma von Willebrand factor.
Shenkman B; Linder N; Savion N; Tamarin I; Dardik R; Kennet G; German B; Varon D
Pediatr Res; 1999 Feb; 45(2):270-5. PubMed ID: 10022601
[TBL] [Abstract][Full Text] [Related]
35. Quantitative assay of a plasma factor deficient in von Willebrand's disease that is necessary for platelet aggregation. Relationship to factor VIII procoagulant activity and antigen content.
Weiss HJ; Hoyer LW; Rickles FR; Varma A; Rogers J
J Clin Invest; 1973 Nov; 52(11):2708-16. PubMed ID: 4542944
[TBL] [Abstract][Full Text] [Related]
36. Dominant von Willebrand disease type 2M and 2U are variable expressions of one distinct disease entity caused by loss-of-function mutations in the A1 domain of the von Willebrand factor gene.
Gadisseur A; van der Planken M; Schroyens W; Berneman Z; Michiels JJ
Acta Haematol; 2009; 121(2-3):145-53. PubMed ID: 19506361
[TBL] [Abstract][Full Text] [Related]
37. Platelet-type von Willebrand disease: a rare, often misdiagnosed and underdiagnosed bleeding disorder.
Othman M
Semin Thromb Hemost; 2011 Jul; 37(5):464-9. PubMed ID: 22102188
[TBL] [Abstract][Full Text] [Related]
38. Type 2B von Willebrand disease and related disorders of patients with increased ristocetin-induced platelet aggregation: what they tell us about the role of von Willebrand factor in hemostasis.
Weiss HJ
J Thromb Haemost; 2004 Nov; 2(11):2055-6. PubMed ID: 15550048
[No Abstract] [Full Text] [Related]
39. Elevated procoagulant microparticles expressing endothelial and platelet markers in essential thrombocythemia.
Trappenburg MC; van Schilfgaarde M; Marchetti M; Spronk HM; ten Cate H; Leyte A; Terpstra WE; Falanga A
Haematologica; 2009 Jul; 94(7):911-8. PubMed ID: 19508974
[TBL] [Abstract][Full Text] [Related]
40. Role of zebrafish thrombocyte and non-thrombocyte microparticles in hemostasis.
Kim S; Carrillo M; Radhakrishnan UP; Jagadeeswaran P
Blood Cells Mol Dis; 2012 Mar; 48(3):188-96. PubMed ID: 22306208
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
